

# Katsuya Tsuchihara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1200419/publications.pdf>

Version: 2024-02-01

70  
papers

2,357  
citations

201575

27  
h-index

223716

46  
g-index

70  
all docs

70  
docs citations

70  
times ranked

4178  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impacts of the STING&#x2D;NFAR1&#x2D;STAT1&#x2D;IRF1 pathway on the cellular immune reaction induced by fractionated irradiation. <i>Cancer Science</i> , 2022, 113, 1352-1361.	1.7	7
2	Comprehensive screening for drugs that modify radiation-induced immune responses. <i>British Journal of Cancer</i> , 2022, , .	2.9	2
3	Impact of learning program on treatment recommendations by molecular tumor boards and an artificial intelligence-based annotation system: A prospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11032-11032.	0.8	0
4	Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1-LBA1.	0.8	52
5	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq1 1 0,784314 rgBT /Ovele	1.0	49
6	Identification of the mutation signature of the cancer genome caused by irradiation. <i>Radiotherapy and Oncology</i> , 2021, 155, 10-16.	0.3	6
7	Amino BODIPY-Based Blue Fluorescent Probes for Aldehyde Dehydrogenase 1-Expressing Cells. <i>Bioconjugate Chemistry</i> , 2021, 32, 234-238.	1.8	10
8	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. <i>Scientific Reports</i> , 2021, 11, 341.	1.6	17
9	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 85-85.	0.8	6
10	Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. <i>Communications Biology</i> , 2021, 4, 438.	2.0	31
11	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3916-3929.	0.4	13
12	Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. <i>Cancer Science</i> , 2021, 112, 3911-3917.	1.7	17
13	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. <i>Cancer Research</i> , 2021, 81, 4835-4848.	0.4	31
14	Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients. <i>Lung Cancer</i> , 2021, 158, 115-125.	0.9	2
15	SCRUM&#x2D;Japan GI&#x2D;SCREEN and MONSTAR&#x2D;SCREEN: Path to the realization of biomarker&#x2D;guided precision oncology in advanced solid tumors. <i>Cancer Science</i> , 2021, 112, 4425-4432.	1.7	24
16	Clinicopathological, gene expression and genetic features of stage I lung adenocarcinoma with necrosis. <i>Lung Cancer</i> , 2021, 159, 74-83.	0.9	5
17	Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams. <i>Biochemical and Biophysical Research Communications</i> , 2021, 585, 55-60.	1.0	11
18	Multifocal origin of occupational cholangiocarcinoma revealed by comparison of multilesion mutational profiles. <i>Carcinogenesis</i> , 2020, 41, 368-376.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. International Journal of Clinical Oncology, 2020, 25, 217-239.	1.0	17
20	International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i> -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. JCO Precision Oncology, 2020, 4, 6-19.	1.5	29
21	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature Medicine, 2020, 26, 1859-1864.	15.2	209
22	Long-read sequencing for non-small-cell lung cancer genomes. Genome Research, 2020, 30, 1243-1257.	2.4	28
23	Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma. Lung Cancer, 2020, 147, 12-20.	0.9	5
24	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. Biomedical Reports, 2019, 11, 171-180.	0.9	4
25	Effect of 5-fluorouracil on cellular response to proton beam in esophageal cancer cell lines according to the position of spread-out Bragg peak. Acta Oncologica, 2019, 58, 475-482.	0.8	5
26	Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry. Journal of Visualized Experiments, 2019, , .	0.2	6
27	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10025-10030.	3.3	41
28	Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer, 2019, 19, 255.	1.1	16
29	Characterization of cancer omics and drug perturbations in panels of lung cancer cells. Scientific Reports, 2019, 9, 19529.	1.6	13
30	Evaluation and application of RNA-Seq by MinION. DNA Research, 2019, 26, 55-65.	1.5	49
31	Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. Scientific Reports, 2018, 8, 3482.	1.6	19
32	Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 893-900.	1.2	7
33	Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. Cancer Research, 2018, 78, 2179-2190.	0.4	33
34	A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nature Communications, 2018, 9, 625.	5.8	75
35	DBTSS/DBKERO for integrated analysis of transcriptional regulation. Nucleic Acids Research, 2018, 46, D229-D238.	6.5	48
36	Reply to "Comment on "Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study". British Journal of Cancer, 2018, 118, 1278-1279.	2.9	0

#	ARTICLE	IF	CITATIONS
37	Identification of potential regulatory mutations using multi-omics analysis and haplotyping of lung adenocarcinoma cell lines. <i>Scientific Reports</i> , 2018, 8, 4926.	1.6	9
38	SCRUM-Japan, a Nation-Wide Cancer Genome Screening and Patient Registry Program. <i>Juntendo Medical Journal</i> , 2018, 64, 191-197.	0.1	2
39	Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia. <i>Lung Cancer</i> , 2018, 126, 162-169.	0.9	2
40	Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis. <i>Lung Cancer</i> , 2018, 126, 182-188.	0.9	17
41	Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer. <i>PLoS ONE</i> , 2018, 13, e0198219.	1.1	13
42	Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 1129.	1.6	7
43	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1 1.0,784314,rgBT /Ome 1.7 38	1.7	38
44	A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. <i>Genome Medicine</i> , 2018, 10, 44.	3.6	37
45	Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. <i>Cancer Science</i> , 2018, 109, 2074-2079.	1.7	10
46	International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3594-3594.	0.8	5
47	Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2017, 77, 2078-2089.	0.4	126
48	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS ( KRAS/NRAS ) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	1.0	13
49	Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 303-313.	1.5	24
50	Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia. <i>Lung Cancer</i> , 2017, 113, 134-139.	0.9	5
51	Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2017, 23, 757-765.	3.2	144
52	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	2.9	52
53	Difference in the relative biological effectiveness and DNA damage repair processes in response to proton beam therapy according to the positions of the spread out Bragg peak. <i>Radiation Oncology</i> , 2017, 12, 111.	1.2	28
54	Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer. <i>DNA Research</i> , 2017, 24, 585-596.	1.5	53

#	ARTICLE	IF	CITATIONS
55	Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. <i>Cancer Science</i> , 2016, 107, 1818-1824.	1.7	46
56	Hypermethylation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes. <i>Carcinogenesis</i> , 2016, 37, 817-826.	1.3	63
57	Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. <i>Genome Biology</i> , 2015, 16, 66.	3.8	66
58	Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2159-2170.	1.2	29
59	Japanese Society of Medical Oncology Clinical Guidelines: KRAS/NRAS mutation testing in colorectal cancer patients. <i>Cancer Science</i> , 2015, 106, 324-327.	1.7	37
60	DBTSS as an integrative platform for transcriptome, epigenome and genome sequence variation data. <i>Nucleic Acids Research</i> , 2015, 43, D87-D91.	6.5	46
61	Genomic profiling of small-cell lung cancer: the era of targeted therapies. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 513-9.	0.6	17
62	Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. <i>Carcinogenesis</i> , 2015, 36, 616-621.	1.3	73
63	Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma. <i>Journal of Biological Chemistry</i> , 2015, 290, 17495-17504.	1.6	144
64	Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 156-64.	1.3	173
65	Effect of a poly(ADP-ribose) polymerase inhibitor against esophageal squamous cell carcinoma cell lines. <i>Cancer Science</i> , 2014, 105, 202-210.	1.7	10
66	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. <i>Nucleic Acids Research</i> , 2014, 42, 13557-13572.	6.5	102
67	A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations. <i>Journal of Clinical Oncology</i> , 2014, 32, 11007-11007.	0.8	1
68	Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Science</i> , 2013, 104, 896-903.	1.7	67
69	RET-targeting molecular stratified non-small-cell lung cancers. <i>Translational Lung Cancer Research</i> , 2013, 2, 463-5.	1.3	1
70	Effects of a lack of Snark on activity, heart rate, and fat and skeletal tissues in mice. <i>FASEB Journal</i> , 2008, 22, 1175.12.	0.2	0